(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
Pertussis cases surge: Over 60,000 reported in Europe; infants most at risk. Maternal vaccination expands: Finland, Norway, and UK updated pregnancy vaccine strategies. BioNet advances: Submitted recombinant pertussis vaccine to EMA; secured EU-GMP approval. Nasal vaccine progresses: ILiAD’s BPZE1 granted … Read the full press release
Posted in Denmark, European Union, Finland, France, Germany, Healthcare, Ireland, News, Norway, Pharma & Biotech, Science, United Kingdom
Tagged acellular pertussis vaccine, Adacel, antibody avidity, antigen dose, ASEAN, Bio Farma, BioNet, biotechnology, booster dose, Boostrix-IPV, BPZE1, certification, Chulalongkorn University, clinical trial, compliance, Dario Cresci, dTap, ECDC, EMA, EU-GMP, EU-GMP certification, EU/EEA, Europe Confronts Pertussis Resurgence as Infant Cases Rise Amid Falling Immunity and Vaccination Gaps, Europe Faces Pertussis Resurgence Amid Waning Immunity and Falling Maternal Vaccination Rates, European Medicines Agency, European Union, European Union Good Manufacturing Practice, Europe’s Pertussis Vaccine Market Opens to New Entrants as Demand Rises, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, GSK, Hanna Nohynek, health policy, HPRA, human challenge trial, hVIVO, ILiAD Biotechnologies, immunization strategy, infant protection, Innovation Passport, Institut Pasteur, intranasal vaccine, Ireland Health Products Regulatory Authority, Lancet Infectious Diseases, maternal vaccination, MHRA, mucosal immunity, outbreak, pandemic recovery, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Phase 3, Philippe Guillot-Chêne, pregnancy immunization, public health, recombinant pertussis vaccine, recombinant pertussis vaccines, regulatory approval, Sanofi, Tdap, TdaP combination vaccine, V, vaccine, vaccine blunting, vaccine development, Vaccine Hesitancy, vaccine pipeline, vaccine rollout, vaccine shortage, vaccine supply, vaccine uptake, VacPertagen, whooping cough
(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
(IN BRIEF) AstraZeneca reported positive Phase III Bax24 trial results showing that baxdrostat achieved a significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in patients with treatment-resistant hypertension. The once-daily oral therapy was well tolerated and maintained … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Advancing Toward Regulatory Submission, AHA 2025, aldosterone, aldosterone synthase inhibitor, ambulatory blood pressure, American Heart Association, AstraZeneca, AstraZeneca’s Baxdrostat Achieves Significant Blood Pressure Reduction in Phase III Bax24 Trial, AstraZeneca’s Baxdrostat Achieves Strong Blood Pressure Reduction in Phase III Bax24 Trial for Resistant Hypertension, Bax24, Baxdrostat, Baxdrostat Delivers Significant 24-Hour Blood Pressure Control in Phase III Study, BaxHTN, Bryan Williams, cardiovascular health, Chronic kidney disease, clinical trial, heart failure prevention, Hypertension Treatment, Phase III results, primary aldosteronism, resistant hypertension, rHTN, SBP, Sharon Barr, systolic blood pressure
(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has received a positive opinion from the EMA’s CHMP for use with a new propellant that offers a 99.9% reduction in Global Warming Potential compared to traditional formulations. Trixeo becomes the first pressurised metered-dose inhaler … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Ambition Zero Carbon, AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, Breztri, BTK inhibitor, budesonide, Calquence, chemoimmunotherapy, CHMP, chronic lymphocytic leukaemia, climate action in pharma, clinical trial, CLL, COPD, Dave Fredrickson, EMA, environmental sustainability, European approval, European Commission approval, European Union, fixed-duration regimen, formoterol fumarate, Frederik Trinkmann, glycopyrronium, hematologic diseases, hematology, Honeywell, inhalers, leukemia, low GWP, next-generation propellant, obinutuzumab, oncology, pMDI, progression-free survival, Respiratory Care, Ruud Dobber, Susanna Palkonen, Sustainable Healthcare, treatment option, Trixeo Aerosphere, venetoclax
(IN BRIEF) AstraZeneca’s Calquence, in combination with venetoclax, with or without obinutuzumab, has been approved by the European Commission for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval follows the positive results from the … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, BTK inhibitor, Calquence, chemoimmunotherapy, chronic lymphocytic leukaemia, clinical trial, CLL, Dave Fredrickson, European Commission approval, European Union, fixed-duration regimen, hematologic diseases, hematology, leukemia, obinutuzumab, oncology, progression-free survival, treatment option, venetoclax
(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Bruton’s tyrosine kinase, BTK inhibitor, clinical data, clinical research, clinical trial, data, disability, disability progression, fenebrutinib, FENopta, Levi Garraway, multiple sclerosis, Phase II, relapse rates, relapsing multiple sclerosis, RMS, Roche, treatment
(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The combination demonstrated significant benefits over BCG alone, with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Bacillus Calmette-Guérin, BCG, bladder cancer, cancer treatment, clinical trial, Cristian Massacesi, disease progression, disease-free survival, durvalumab, high-risk bladder cancer, Imfinzi, immunotherapy, Maria De Santis, NMIBC, non-muscle-invasive bladder cancer, Phase III Trial, POTOMAC
(IN BRIEF) The University of Glasgow is leading the innovative FOxTROT 5 trial, which is offering elderly colon cancer patients the opportunity to participate in a groundbreaking immunotherapy study. The trial will administer dostarlimab before surgery, targeting a specific type … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged cancer research, cancer treatment, chemotherapy, clinical trial, clinical trial protocol, colon cancer, deficient mismatch repair, dMMR, dostarlimab, Elderly Patients, FOxTROT 5, frail patients, GSK, immunotherapy, partnership, precision oncology, surgery, UK hospitals, University of Birmingham, University of Glasgow, University of Leeds
(IN BRIEF) The EU-funded DORIAN GRAY project, with the University of Liverpool as a key scientific partner, is set to explore the link between cardiovascular disease (CVD) and mild cognitive impairment (MCI). Despite one in three CVD patients experiencing MCI, … Read the full press release
Posted in Education, Healthcare, Science, Society, United Kingdom
Tagged AI, biomarkers, cardiovascular disease, clinical trial, cognitive training, CVD, dementia reduction, digital tool, DORIAN GRAY, Dr Riccardo Proietti, EU-funded, heart failure, Horizon Europe, international collaboration, Liverpool Clinical Trials Centre, MCI, medical avatar, mild cognitive impairment, Prevention Strategies, Professor Carrol Gamble, risk model, University of Brescia, University of Liverpool
(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adjuvant, AstraZeneca, clinical trial, Cristian Massacesi, durvalumab, early-stage, EFS, event-free survival, FLOT chemotherapy, gastric cancer, gastroesophageal junction, GEJ cancers, global, Imfinzi, immunotherapy, locally advanced, MATTERHORN, Memorial Sloan Kettering, neoadjuvant, OS, overall survival, pathologic complete response, PCR, Phase III Trial, randomized, resectable, safety profile, tumor regression, Yelena Y. Janjigian
(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged abiraterone, AKT inhibitor, biomarkers, clinical trial, genetic markers, Institute of Cancer Research London, ipatasertib, IPATential150 trial, metastatic castration-resistant prostate cancer mCRPC, overall survival, personalized medicine, PIK3CA/AKT1/PTEN pathway, Professor Johann de Bono, PTEN gene, Roche, sequencing techniques, synthetic lethality, targeted therapy, UK patients
(IN BRIEF) Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupixent would be the first targeted medicine for BP in the U.S., with the FDA’s decision expected … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged bullous pemphigoid, chronic conditions, clinical trial, corticosteroid, disease remission, Dupixent, Dupixent sBLA, FDA approval, FDA priority review, orphan drug designation, regulatory news, Sanofi, skin disease, targeted treatment
(IN BRIEF) The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel in London. This event offers a platform for pharma R&D and patient advocacy to discuss … Read the full press release
Posted in France, Healthcare, Marketing, Pharma & Biotech, Science, Switzerland, United Kingdom
Tagged Alfred Samuels, AstraZeneca, Azafaros, Beyza Klein, Biotech, Biotechnology Conference, Boehringer Ingelheim, Bre Bugbee-Barrett, Catherine Coulouvrat MD, Chiesi Farmaceutici SpA, clinical development, clinical operations, clinical research, clinical research enterprise, clinical trial, clinical trials, Conference Forum, decentralized clinical trials, Gisela Linthorst, GSK, Harry Verbunt, HTA/Regulatory requirements, Johnson & Johnson Innovative Medicine, Lea-Isabelle Proulx PhD, life post-cancer diagnosis, Marisa Minetti, Medicine Development, Patient Advocacy, patient engagement, patient engagement in drug development, patient experience, Patient Recruitment, Patient Retention, Patients as Partners, Patients as Partners Europe, Peter DiBiaso, pharma, Pharmaceutical Conference, Regeneron, research and development, Roche, Royal National Hotel, Sanofi, Temi Olonisakin MD, The Conference Forum, Valerie Bowling
(IN BRIEF) ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and older. This approval offers a significant advancement in HIV care, providing an injectable treatment option that reduces the … Read the full press release
Posted in Business, European Union, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged adolescents, clinical trial, European Commission, GSK, Healthcare Innovation, HIV care, HIV treatment, HIV treatment options, long-acting injections, MOCHA study, partnership, Rekambys, ViiV Healthcare, Vocabria
(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Technology
Tagged clinical research project, clinical trial, computerized Tomography, diagnostics, DOTA-TATE Positron Emission Tomography, Dr. Harald Hasselmann, Eckert & Ziegler, Ga-68, GalliaPharm®, Gallium-68, Ge-68, Japan, Japanese Pharmaceuticals and Medical Devices Agency, NCT06240741, NEN, neuroendocrine neoplasms, Novartis Pharma K.K., PET, PMDA, radioisotope supply, rare tumors
(IN BRIEF) The Paul Scherrer Institute (PSI) has administered proton radiotherapy to a 67-year-old patient with oesophageal cancer, marking the first time this treatment has been used in Switzerland for such a case. The treatment is part of a collaborative … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Science, Switzerland, Technology
Tagged clinical trial, Damien Weber, Dominic Leiser, Matthias Guckenberger, Oesophageal Cancer, Panagiotis Balermpas, Paul Scherrer Institute, PROTECT (PROton versus photon Therapy for Esophageal Cancer: a Trimodality Strategy), Proton Radiotherapy, Switzerland, treatment, University Hospital Zurich, wellness
(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release
(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. This … Read the full press release
Posted in Education, Healthcare, Internet & Online, News, Pharma & Biotech, Science, Technology
Tagged 6th annual EU Patients as Partners, AbbVie, Biotech, clinical development, clinical research, clinical trial, clinical trials, Conference, Conference Forum, data, dct, decentralized, DNA, EMD Serono, Gilead Sciences, GSK, INNOVATION, Ipsen, Janssen, Johnson & Johnson, Medicines Development, Merck KGaA, Michaela Dinboeck, MS trial, Noema Pharma, Novartis, Parkinsons disease, patient engagement, patient input, Patient Voice, patients, Patients as Partners Europe, Pfizer, pharma, Pharmaceutical, Pierre Fabre, Regeneron, Takeda, UCB
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?